SALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies ...

Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...

Myriad Genetics partners with broadcaster Hannah Storm to promote breast cancer risk assessment and the importance of family health history. Myriad Genetics, Inc. has announced a collaboration with ...

Myriad Genetics has grown from a mainly Hereditary Cancer business into a broader precision medicine company. Click here to ...

SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed ...

SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research ...

Prospective Clinical Study Showed the myRisk Test Identified 70 Percent More Deleterious Mutations than BRCA Testing Alone with 42 Percent of These in Women Over Age 45 Myriad Genetics, Inc. (NASDAQ: ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 36.4% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and ...

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...